Screener
Aurinia Pharmaceuticals AUPH Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Aurinia Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 8:16 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001600620-26-000062
FAQ
- What is Aurinia Pharmaceuticals's retained earnings?
- Aurinia Pharmaceuticals (AUPH) reported retained earnings of -$577.6M in Q2 2026.
- How has Aurinia Pharmaceuticals's retained earnings changed year-over-year?
- Aurinia Pharmaceuticals's retained earnings increased by 35.2% year-over-year, from -$891.71M to -$577.6M.
- What is the long-term trend for Aurinia Pharmaceuticals's retained earnings?
- Over 5 years (2020 to 2025), Aurinia Pharmaceuticals's retained earnings has grown at a 2.5% compound annual growth rate (CAGR), from -$575.16M to -$649.37M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Aurinia Pharmaceuticals's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude